Journal for ImmunoTherapy of Cancer: Effects of oncolytic immunotherapy with RP1 (vusolimogene oderparepvec) on immune cells mediate responsiveness to anti-PD-1 via STING-mediated interferon Mar 03, 2026 Journal of Clinical Oncology: RP1 Combined With Nivolumab in Advanced Anti–PD-1– Failed Melanoma (IGNYTE) Nov 30, 2025
Journal for ImmunoTherapy of Cancer: Effects of oncolytic immunotherapy with RP1 (vusolimogene oderparepvec) on immune cells mediate responsiveness to anti-PD-1 via STING-mediated interferon Mar 03, 2026
Journal of Clinical Oncology: RP1 Combined With Nivolumab in Advanced Anti–PD-1– Failed Melanoma (IGNYTE) Nov 30, 2025